This program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC.
Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, talk about the practical use of biomarkers in treatment decision making.
This program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC.
Tanuja Chitnis, MD, explains how higher neurofilament light chain levels can signal disease activity in MS.
The founder and executive director of the Sumaira Foundation shared her patient perspective of Health Canada’s approval of inebilizumab in terms of its implications for patients and how it paves the way for future treatments in NMOSD. [WATCH TIME: 3 minutes]
The chief executive officer of ClearPoint Neuro discussed how the company’s SmartFrame OR Stereotactic System can facilitate neurosurgery and the next steps in integrating it into clinical settings. [WATCH TIME: 4 minutes]
Neurology News Network for the week ending January 27, 2024. [WATCH TIME: 3 minutes]
The associate professor, department of medicine, division of neurology, Institute of Medical Science, University of Toronto, shared his thoughts on potential therapies and expanding care options for sleep disorders in 2024. [WATCH TIME: 5 minutes]
The chief executive officer of Aruna Bio discussed the mechanism of action behind AB126 and how its anti-inflammatory and neuroprotective properties may be effective in treating acute ischemic stroke. [WATCH TIME: 4 minutes]
The European evidence generation strategy lead for epilepsy and rare syndromes at UCB described some details about further epilepsy research and other explorations in the next few years. [WATCH TIME: 3 minutes]
The health economics outcomes research specialist at UCB discussed the need for improved methodologies to have a more accurate analysis of patient outcomes beyond what administrative databases can provide. [WATCH TIME: 2 minutes]
The staff neurologist from the Mellen Center for MS Treatment and Research at the Cleveland Clinic provided perspective on recently published research showing geographic disparities to neurologists and multiple sclerosis centers. [WATCH TIME: 3 minutes]
The head of Patient Engagement, Epilepsy and Rare Syndromes (Europe) at UCB Pharma discussed the inconsistencies in educational information given to patients with epilepsy, including the knowns of sudden unexpected death. [WATCH TIME: 4 minutes]
The director of Geriatric Psychiatry at the St Louis University School of Medicine talked about BXCL501 as a potential treatment for acute agitation in patients with Alzheimer disease and how it compares with brexpiprazole, the first approved therapy. [WATCH TIME: 4 minutes]
The medical director of the Inpatient Rehabilitation Unit at Ascension Genesys Hospital discussed the importance of early intervention, sustained care, and rehabilitation in managing poststroke patients. [WATCH TIME: 4 minutes]
The epileptologist at NYU Langone Health and associate professor of neurology at the NYU Grossman School of Medicine shared her thoughts on potential therapies and expanding management care options for patients with epilepsy in the near future. [WATCH TIME: 5 minutes]
This program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC.
Ahmed Obeidat, MD, PhD, recounts the difficulties with MRI as a main biomarker for MS and shares strategies for optimal use of the technology.
This program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC.
Tanuja Chitnis, MD, discusses the use of ultra-sensitive assays to determine protein levels in the blood, which may aid in the diagnosis of MS.
The professor of neurology at Cedars-Sinai Medical Center shared his thoughts on potential therapies that expand management care options for patients with neuromuscular disease, in particularly for chronic inflammatory demyelinating polyneuropathy. [WATCH TIME: 4 minutes]
The professor of neurology at Cedars-Sinai Medical Center shared his clinical perspective on the recent FDA approval of Takeda’s immune globulin infusion, Hyqvia, for chronic inflammatory demyelinating polyneuropathy. [WATCH TIME: 5 minutes]
Neurology News Network for the week ending January 21, 2024. [WATCH TIME: 3 minutes]
The director of the Hartford healthcare Headache Center in Connecticut shared his and colleagues' thoughts on potential therapies that expand management care options for patients with migraine. [WATCH TIME: 7 minutes]
The director of NYU Langone’s Comprehensive Epilepsy Center discussed a recently published study that used videos to identify potential causes of sudden deaths in toddlers. [WATCH TIME: 4 minutes]
The head of Patient Engagement, Epilepsy and Rare Syndromes (Europe) at UCB Pharma discussed findings from a literature review presented at AES 2023 involving conversations about sudden unexpected death in epilepsy. [WATCH TIME: 4 minutes]
The medical director of the Inpatient Rehabilitation Unit at Ascension Genesys Hospital explored the various interventions for managing spasticity after stroke, from stretching exercises to surgical procedures. [WATCH TIME: 3 minutes]
The system vice chair for the department of neurology at Allegheny Health Network talked about the growing evidence emphasizing the need for a more holistic approach to patient care in migraine. [WATCH TIME: 4 minutes]
The clinical director of Parkinson & Movement Disorder Alliance shared her thoughts on potential therapies to increase management care options for patients with Parkinson disease. [WATCH TIME: 5 minutes]
This program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC.
Ahmed Obeidat, MD, PhD, considers utility of biomarkers in MS diagnosis, but he also noted that diagnosis remains clinical.
This program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC.
Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, discuss the role of biomarkers and the key areas in which they will be used in managing day-to-day decisions in patient management.
The associate professor in the department of neurology at Mayo Clinic College of Medicine talked about the importance of adopting a patient-centered approach in migraine treatment and the often overlooked impact of brain fog in patients with migraine. [WATCH TIME: 4 minutes]
The chief medical research officer and head of research at Aviv Clinics talked about the anticipation of long-term results on a randomized controlled trial assessing hyperbaric oxygen therapy, a treatment for long COVID. [WATCH TIME: 5 minutes]
The associate professor, department of medicine, division of neurology, Institute of Medical Science, University of Toronto, discussed recent research that challenged the conventional definitions of sleep and how narcolepsy is often stigmatized. [WATCH TIME: 2 minutes]
